Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients | Zendy

Rebecca Evans | Zendy; Haruhide Kimura | Zendy; Robert Alexander | Zendy; Ceri H. Davies | Zendy; Hélène M. Faessel | Zendy; Deborah Hartman | Zendy; Takashi Ishikawa | Zendy; Emiliangelo Ratti | Zendy; Kohei Shimizu | Zendy; Motohisa Suzuki | Zendy; Shinichiro Tanaka | Zendy; Hiroshi Yukitake | Zendy; Yves Dauvilliers | Zendy; Emmanuel Mignot | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Author(s) -

Rebecca Evans,

Haruhide Kimura,

Robert Alexander,

Ceri H. Davies,

Hélène M. Faessel,

Deborah Hartman,

Takashi Ishikawa,

Emiliangelo Ratti,

Kohei Shimizu,

Motohisa Suzuki,

Shinichiro Tanaka,

Hiroshi Yukitake,

Yves Dauvilliers,

Emmanuel Mignot

Publication year - 2022

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.2207531119

Subject(s) - narcolepsy , orexin , wakefulness , agonist , cataplexy , endocrinology , medicine , sleep (system call) , orexin receptor , receptor , neuroscience , biology , pharmacology , neuropeptide , modafinil , electroencephalography , computer science , operating system

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research